Advertisement

 

 

Emerging Biomarkers of lymphangioleiomyomatosis.

Emerging Biomarkers of lymphangioleiomyomatosis.
Author Information (click to view)

Nijmeh J, El-Chemaly S, Henske EP,


Nijmeh J, El-Chemaly S, Henske EP, (click to view)

Nijmeh J, El-Chemaly S, Henske EP,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of respiratory medicine 2017 11 24() doi 10.1080/17476348.2018.1409622

Abstract
INTRODUCTION
Lymphangioleiomyomatosis (LAM) is a destructive lung disease affecting primarily women. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes, resulting in hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Over the past five years, there have been remarkable advances in the diagnosis and therapy of LAM, including the identification of vascular endothelial growth factor D (VEGF-D) as a diagnostic biomarker and the US Food and Drug Administration approval of sirolimus as therapy for LAM. In appropriate clinical situations VEGF-D testing can make lung biopsy unnecessary to diagnose LAM. However, there remains an urgent unmet need for additional biomarkers of disease activity and/or response to therapy. Areas covered: This work reviews VEGF-D, an established LAM biomarker, and discusses emerging biomarkers, including circulating LAM cells, imaging, lipid and metabolite biomarkers, focusing on those with the highest potential impact for LAM patients. Expert commentary: Ongoing research priorities include the development of validated biomarkers to 1) non-invasively diagnose LAM in women whose VEGF-D levels are not diagnostic, 2) accurately predict the likelihood of disease progression and 3) quantitatively measure disease activity and LAM cell burden. These biomarkers would enable personalized, precision clinical care and fast-track clinical trial implementation, with high clinical impact.

Submit a Comment

Your email address will not be published. Required fields are marked *

17 − six =

[ HIDE/SHOW ]